Blueprint Medicines (BPMC) 24th Annual Needham Virtual Healthcare Conference summary

Strategic priorities and financial outlook

• Focused on therapies for mast cell disorders, with Ayvakit leading and Elenestinib and BLU-808 advancing in development.

• Ayvakit projected to reach $680–$710 million in 2024 revenue, targeting $2 billion by 2030, with a potential $4 billion portfolio opportunity.

• Strong financial position with declining cash burn and disciplined investment in top priorities.

• Supply chain spans US, Europe, and Canada; tariffs have minimal financial impact.

• IP for Ayvakit is domiciled in the US, supporting business stability.

Market dynamics and growth drivers

• Systemic mastocytosis (SM) market is expanding, with US prevalence estimated at 60,000–65,000 patients.

• Growth driven by increased diagnosis, physician adoption, and high patient compliance with Ayvakit.

• Medicare Part D changes improved access, positively impacting revenue mix.

• International growth, especially in Europe, expected to contribute 10–15% of revenue, with Germany as a pricing benchmark.

• Ongoing efforts to expand diagnosis through advanced blood-based testing and awareness initiatives.

Product pipeline and clinical development

• Elenestinib entered a registration-enabling study, aiming for differentiation through endpoints like bone health and anaphylaxis.

• BLU-808, a wild-type KIT inhibitor, is in proof-of-concept studies for allergic and inflammatory disorders.

• Multiple proof-of-concept studies for BLU-808 will inform dose selection and indication prioritization, with initial data expected late this year or next.

• Protein degrader platform advancing, with CDK4 degrader expected to reach development candidate status this year.